Sugi Predict

Sugi Predict / Compounds / SCHEMBL6847689

SCHEMBL6847689

SCHEMBL6847689

O=C(CCNC(O)c1ccccc1)c1ccc(Br)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.49
▸ DAO P14920 1/20 0.42
▸ NPSR1 Q6W5P4 3/20 0.42
▸ GAA P10253 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ MAPT P10636 4/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CES2 O00748 1/20 0.40
▸ CES1 P23141 1/20 0.40
▸ MITF O75030 2/20 0.39
▸ OXTR P30559 1/20 0.39
▸ AVPR1A P37288 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ ACKR3 P25106 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6848101 0.86 GSK3B (0.46) GSK3BDAONPSR1GAARXFP1
SCHEMBL6847892 0.84 GSK3B (0.47) GSK3BDAONPSR1GAARXFP1
SCHEMBL13518266 0.83 GSK3B (0.46) GSK3BDAONPSR1GAARXFP1
SCHEMBL13518658 0.83 GSK3B (0.46) GSK3BDAONPSR1GAARXFP1
SCHEMBL13517465 0.82 ALDH1A1 (0.45) GSK3BDAONPSR1GAARXFP1
SCHEMBL6847010 0.82 KDM4E (0.47) GSK3BDAONPSR1GAARXFP1
SCHEMBL6848126 0.79 GSK3B (0.56) GSK3BDAONPSR1GAARXFP1
SCHEMBL6847513 0.77 KMT2A (0.45) GSK3BDAONPSR1GAARXFP1
SCHEMBL13517361 0.76 GSK3B (0.49) GSK3BDAONPSR1GAARXFP1
SCHEMBL6847853 0.75 GSK3B (0.51) GSK3BDAONPSR1GAARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937091-B2 Inhibitor of protein crosslinking and use of the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-01-20 — — US disclosed
US-8937091-B2 Inhibitor of protein crosslinking and use of the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-01-20 — — US disclosed
US-8937091-B2 Inhibitor of protein crosslinking and use of the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-01-20 — — US disclosed
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY 2012-11-01 — — US disclosed
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY 2012-11-01 — — US disclosed
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY 2012-11-01 — — US disclosed
WO-2011055561-A1 PROTEIN CROSSLINKING INHIBITOR AND USE THEREOF 独立行政法人科学技術振興機構 (JP) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME ARGLU1, F12, CDKL1 GSK3B 2593/4885DAO 581/4885NPSR1 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.